Corbus Pharmaceuticals Holdings (CRBP) Interest Expenses (2013 - 2025)
Corbus Pharmaceuticals Holdings (CRBP) posted quarterly Interest Expenses of $371000.0 for Q4 2025, up 615.28% year-over-year from $51868.0 in Q4 2024, and down 87.8% quarter-over-quarter from $3.0 million in Q1 2025.
Corbus Pharmaceuticals Holdings (CRBP) Interest Expenses (2013 - 2025) Analysis & Trends
Corbus Pharmaceuticals Holdings' Interest Expenses history runs 13 years deep, the most recent figure standing at $371000.0 for Q4 2025.
- In Q4 2025, Interest Expenses rose 615.28% year-over-year to $371000.0; the TTM figure through Dec 2025 stood at $371000.0 (down 84.04% YoY), while the FY2025 annual figure was $371000.0, down 86.83% from the prior year.
- Interest Expenses for Q4 2025 stood at $371000.0, down from $3.0 million in the prior quarter.
- The five-year high for Interest Expenses was $38.8 million in Q3 2021, with the low at -$72000.0 in Q4 2024.
- The 5-year median for Interest Expenses is $2.8 million (2024), against an average of $11.1 million.
- The sharpest annual moves came in 2024 and 2025: Interest Expenses plunged 111.59% in 2024, then surged 615.28% in 2025.
- Corbus Pharmaceuticals Holdings' Interest Expenses stood at $435366.0 in 2021, then jumped by 288.13% to $1.7 million in 2022, then tumbled by 63.25% to $621000.0 in 2023, then slumped by 111.59% to -$72000.0 in 2024, then soared by 615.28% to $371000.0 in 2025.
- Business Quant data shows CRBP's Interest Expenses at $371000.0 in Q4 2025, $3.0 million in Q1 2025, and -$72000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Corbus Pharmaceuticals Holdings | 127.63 Mn | -35.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 371,000.00 |
| Dec 31, 2025 | 371,000.00 |
| Mar 31, 2025 | 3.04 Mn |
| Mar 31, 2025 | 3.04 Mn |
| Dec 31, 2024 | -72,000.00 |
| Dec 31, 2024 | -72,000.00 |
| Sep 30, 2024 | 2.60 Mn |
| Sep 30, 2024 | 2.60 Mn |
| Jun 30, 2024 | 12.17 Mn |
| Jun 30, 2024 | 12.17 Mn |
| Mar 31, 2024 | 839,000.00 |
| Mar 31, 2024 | 839,000.00 |
| Dec 31, 2023 | 621,000.00 |
| Dec 31, 2023 | 621,000.00 |
| Sep 30, 2023 | 20.82 Mn |
| Sep 30, 2023 | 20.82 Mn |
| Jun 30, 2023 | 20.77 Mn |
| Jun 30, 2023 | 20.77 Mn |
| Mar 31, 2023 | 937,000.00 |
| Mar 31, 2023 | 937,000.00 |